Is Option Care Health (OPCH) the Best Performing Healthcare Stock to Buy Now?
We recently published a list of . In this article, we are going to take a look at where Option Care Health, Inc. (NASDAQ:OPCH) stands against other best performing healthcare stocks to buy now.
On April 15, CNBC reported that President Trump's healthcare-focused executive order brought in a win for the sector. Trump directed his health department to collaborate with Congress to revamp a law allowing Medicare to negotiate prescription drug prices. The announcement seeks to bring a change that the pharmaceutical company has lobbied for. Since the negotiation process is included in legislation, Trump's executive order cannot implement the change itself. However, it directs Secretary of Health and Human Services Robert F. Kennedy Jr. to join hands with Congress and change it.
CNBC reported that drug makers have been working to delay the eligibility timeline for small-molecule drugs to be available for price negotiations by four years. This typically includes pills and most medications. This goes hand in hand with the 13-year wait until more complex biotech drugs are eligible for Medicare price negotiations.
Trump's wide-ranging executive order also focuses on slashing healthcare costs. It comes a day after the administration instituted a national security report on the pharma industry. CNBC called the report 'a precursor to sector-specific tariffs.'
READ ALSO: Recession Resistant Investing: 10 Best Grocery Stocks To Buy Now and 11 Most Promising Future Stocks According to Hedge Funds.
Medicare's negotiating powers have been a subject of contention, as drug makers have opined that they would suppress innovation and have rallied against the time frame for negotiation eligibility for most drugs. The law now allows the government to negotiate prices for drugs with no competition, which includes complex biotech or biologic medications after 13 years on the market, but 9 years for their administration as capsules and pills.
Although they did not provide specifics, White House officials told reporters that other changes to the negotiation process would yield more savings than those attained during the first round under the Biden administration. While the Biden administration negotiated price cuts as steep as 79% for the first ten most expensive drugs to the Medicare program, the Trump administration would negotiate prices for the following 15 medications. This includes Pfizer's cancer drugs Ibrance and Xtandi, as well as Novo Nordisk's blockbuster diabetes and weight-loss treatments Ozempic and Wegovy.
We used Finviz to screen healthcare stocks and selected the best performers based on their year-to-date (YTD) performance, as of May 9, 2025. We also included the number of hedge fund holders for each stock as of Q4 2024. We sourced the hedge fund sentiment data from Insider Monkey's database. The list is sorted in ascending order of year-to-date performance.
Why do we care about what hedge funds do? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points ().
A home infusion nurse in full PPE gown delivering treatments to a patient in their own home.
YTD Performance: 37.24%
Number of Hedge Fund Holders: 40
Option Care Health, Inc. (NASDAQ:OPCH) provides infusion therapy and similar ancillary healthcare services through a national network of full-service pharmacies. It holds contracts with hospitals, physicians, third-party payers, managed care organizations, and other referral sources to provide complex compounded solutions and pharmaceuticals to patients. The company's home infusion services include bleeding disorder therapies, nutrition support, anti-infectives, and more.
On April 30, UBS analyst A.J. Rice upgraded the rating on Option Care Health, Inc. (NASDAQ:OPCH) to a Buy and set a price target of $40.00, highlighting the company's strategic positioning and strong financial performance. The company's fiscal Q1 2025 financials also reflected a robust earnings momentum.
Effective inventory management supports the analyst's belief that the impact of STELARA, a prescription drug that treats moderate to severe plaque psoriasis, will be less severe than expected. STELARA's integration in Option Care Health, Inc.'s (NASDAQ:OPCH) earnings is anticipated to support long-term growth. This is especially true as the healthcare industry shifts care from institutional settings to home, which is proving beneficial to Option Care Health, Inc.'s (NASDAQ:OPCH) diversified drug portfolio.
The analyst also reasoned that the company's solid free cash generation ability and balance sheet position it well for strategic acquisitions in a fragmented market, supporting the buy rating. The company is also well-positioned to manage potential tariff impacts through its inventory management, strategic contracts, and risk mitigation related to cost inflation.
Overall, OPCH ranks 9th on our list of the best performing healthcare stocks to buy now. While we acknowledge the potential for OPCH as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than OPCH but trades at less than 5 times its earnings, check out our report about this cheapest AI stock.
READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.
Disclosure: None. This article is originally published at Insider Monkey.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
15 minutes ago
- Yahoo
Exclusive: Trump's tariff deal ‘quietly' added 10% raise which nobody is complaining about anymore, says his former commerce secretary
Wilbur Ross, former Commerce Secretary and a key architect of Trump's first-term trade policy, describes Trump's current tariff strategy as a deliberate evolution: moving faster, hitting harder, and using broader executive powers to impose tariffs for both economic and diplomatic leverage. The Trump administration's use of tariffs has sparked debate over the ultimate goals of its economic strategy. However, a former Cabinet member and key trade advisor to the President has suggested there is an underlying logic to the approach. Since winning the Oval Office, President Trump has announced an evolving range of policies. with economic sanctions spinning higher on some trade partners while others have been granted pauses. Many of the announcements have not come through official White House channels; for example, Trump threatened a 50% tariff on the EU in April in a bid to get European negotiators to the table—by posting on his social media site, Truth Social. Indeed, Trump has come under scrutiny from Beijing, arguably the most critical region for the U.S. to make a deal, who claim America's tariff tactics have been 'coercion and blackmail' when instead it should 'convey information to the Chinese side…through relevant parties.' But Wilbur Ross, Trump's Commerce Secretary in his first administration, says there's a clear tactic at play beneath Trump's bluster. The 87-year-old banker turned D.C. power player said there is an 'art' to Trump's dealmaking, as White House Press Secretary Karoline Leavitt has suggested; Ross told Fortune in an exclusive interview: 'Well, everybody's reaction to [tariffs] was first shock and amazement, but the actual retaliatory measures that they put in were fairly modest—even China didn't match in dollar for dollar. 'There's a real reason for that, I think the other countries, as they've thought about it, have recognized that while they have to talk very bravely for their domestic political constituencies… They also recognize that at the end of the day, they can't afford a tit-for-tat escalating trade war with us.' And this was a fact Trump was relying on, continued Ross: 'One of the earliest things he put in was that 10% tariff on everything from everywhere. 'Nobody is even complaining about that anymore. When you think about it, in the normal course, getting quietly to do a 10% tariff on everything from everywhere was a huge achievement, even if he didn't get anything else. But because he followed it with these much more extreme things, it makes the 10% look like it's not such a big bother. 'But it's a huge number, and he's been collecting it every day.' Indeed, imported goods alone into the U.S. in 2024 stood at $3.36 trillion—even before tax, duties, and levies were collected (worth $82 billion) and before imported services are added to those figures. Even 10% of near-$3.4 trillion is an eye-watering sum to add to federal budgets, though some items like autos and steel are even higher. Indeed nations like China, Canada, and Mexico are all already subject to more than the baseline 10% universal tariff. When Ross spoke to Fortune in a previous exclusive interview earlier this year, he said President Trump would be all the more confident in his second term because he now better understands the inner workings of Washington, D.C., and has a stronger mandate courtesy of a solid election sweep. And President Trump's tactics, which have included everything from threatening a 25% hike on Apple's iPhones specifically to raising sanctions to more than 150% on China at some points, reflect the path Ross expected. After all, as Secretary, Ross was one of the key allies in Trump's team when renegotiating America's position on the North American Free Trade Agreement (NAFTA). At the time, Trump was a fierce critic of the deal with Mexico and Canada and wanted to withdraw from the agreement and begin negotiating from there. Ross felt the better tactic was to threaten such action and keep an exit as a last resort, an opinion that Trump eventually came around to agreeing with. Likewise, having been appointed in 2017 Ross oversaw the tariff action in the first Trump administration which included sanctions on Chinese goods as well as aluminum and steel more widely. 'He has started out on a much more adventurous path than last time,' Ross told Fortune this week. 'Broader in scope and more extreme in terms of the numbers themselves.' Trump has three objectives, he adds: shrinking trade deficits, producing revenue to offset his 'One Big, Beautiful Bill' and achieving other diplomatic purposes such as the flow of fentanyl into the U.S. and global defense spending. 'He has a much more fulsome, much more complicated agenda than before,' Ross explains. 'It's also different in…that last time I was very careful to set the groundwork to do public hearings, stakeholder meetings, to do written reports, to set a whole record so that under the Administrative Procedures Act we would be relatively safe from people trying to knock it out in court. 'This time, they did a very different thing. They went in mostly just by his say so using the IFA, the Emergency Powers Act, and they ran into a snag at the Court for International Trade.' This snag may alter the course of tariff reaction on the account of businesses, he added, because their investment timelines may shift based on when the tariffs are legally approved. But Ross added: 'Most people are operating under the assumption that sooner or later, he'll get something like what he was looking for…and therefore, while it's slowed down a bit, [I] don't think it will derail [trade talks] because [foreign governments] also know there are other ways he could punish them rather than just the tariffs. 'So it's a bump in the road, but I don't think it's a huge pothole that would wreck the car.' This story was originally featured on
Yahoo
16 minutes ago
- Yahoo
Oil prices jump after Israel's attack on Iran and it could lead to higher gas costs
Oil prices have jumped following Israel's attack on Iran as experts warn the conflict could lead to higher gas costs. The price of a barrel of benchmark U.S. crude jumped 6.8 percent to $72.65 Friday. Brent crude, the international standard, rose 7.1 percent to $74.30 a barrel. 'Gas prices will likely start to rise across much of the country later this evening in response to Israel's attacks on Iran, which have caused oil prices to surge. For now, I expect the rise to be noticable, but limited. Approx 10-25c/gal thus far, but this could change,' industry expert Patrick De Haan wrote on X. Iran is one of the world's major producers of oil and if a wider war escalates, it could slow the flow of Iranian oil to U.S. customers and elsewhere. 'Iran knows full well that Trump is focused on lower energy prices and actions by Iran that impact Middle East supply and consequently raise oil prices damage Trump politically,' Andy Lipow, president of Lipow Oil Associates consulting firm, told CNN. Past attacks involving Iran and Israel have seen prices for oil spike initially, only to fall later 'once it became clear that the situation was not escalating and there was no impact on oil supply,' said Richard Joswick, head of near-term oil at S&P Global Commodity Insights. The Secretary of the Organization of the Petroleum Exporting Countries warned industry executives not to 'raise false alarms.' 'There are currently no developments in supply or market dynamics that warrant unnecessary measures,' the organization said on X. Israel said 200 fighter jets took part in strikes on more than 100 targets in Iran overnight in an escalation that threatens to spark a wider conflict in the Middle East. Israel said Iran has launched more than 100 drones towards Israel in response - but Tehran has denied these reports, according to Iranian media. Trump firmly put the U.S. in Israel's corner after the attacks. The president said he'd given Tehran 'chance after chance to make a deal' that would have headed off the strikes by putting restrictions on the country's nuclear weapons program and complained that Iranian negotiators had never been able to come to an agreement. 'I gave Iran chance after chance to make a deal. I told them, in the strongest of words, to 'just do it,' but no matter how hard they tried, no matter how close they got, they just couldn't get it done,' he wrote on Truth Social. Trump also said he'd warned Iran that Israel 'has a lot' of American-made military hardware — 'the best and most lethal' — and is quite proficient in using it. 'Certain Iranian hardliner's spoke bravely, but they didn't know what was about to happen. They are all DEAD now, and it will only get worse!' he added. 'Iran must make a deal, before there is nothing left. No more death, no more destruction, JUST DO IT, BEFORE IT IS TOO LATE,' the president wrote. The Associated Press contributed reporting Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Wall Street Journal
17 minutes ago
- Wall Street Journal
If Not Washington, Who Will Fund Harvard?
Jason Riley describes how Harvard has become a punching bag for political grandstanding ('Does the President Want to Fix Harvard or Destroy It?,'Upward Mobility, May 28). Yet the Trump administration swings at its peril. Harvard isn't a delicate orchid that will fold under political heat. It's a $53 billion juggernaut with labs, patents and partnerships that span the globe. If Washington starts revoking grants, threatening tax status or chilling academic freedom to score points with the base, Harvard isn't going to sit tight until President Trump is over. It's going to pivot—aggressively. Someone else, be it Berlin, Seoul or Abu Dhabi, will fund it. The idea that the greatest minds in medicine, energy and artificial intelligence will suddenly transfer their breakthroughs to a U.S. government-licensed trade school is laughable. In a century where data, biotech and artificial intelligence are the new oil, dismantling our own research powerhouse is like banning railroads in 1900 because the engineers read Karl Marx.
